Lazabemide

Drug Profile

Lazabemide

Alternative Names: Pakio; RO 196327; Tempium

Latest Information Update: 24 Sep 1999

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antiparkinsonians; Nootropics; Picolinic acids; Small molecules; Smoking cessation therapies
  • Mechanism of Action Antioxidants; Monoamine oxidase B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Alzheimer's disease; Parkinson's disease; Smoking withdrawal

Most Recent Events

  • 24 Sep 1999 Discontinued-Clinical for Smoking withdrawal (PO)
  • 24 Sep 1999 Discontinued-I for Parkinson's disease in New Zealand (PO)
  • 24 Sep 1999 Discontinued-III for Alzheimer's disease in Europe (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top